Program Committee

Dana Goldman, PhD
Chair, Professor, USC Schaeffer Center for Health Policy & Economics, Los Angeles, California, USA

Jan Elias Hansen, PhD
Vice President, Evidence for Access Unit, US Medical Affairs at Genentech, South San Francisco, CA, USA

Nicola Bedlington
Special Advisor, European Patients' Forum, Brussels, Belgium
Research Review Committee
Josh
J. Carlson, MPH, PhD
Associate Professor, The Comparative Health
Outcomes, Policy, and Economics, (CHOICE) Institute, School of Pharmacy,
University of Washington, Seattle, WA, USA
Laura A. Hatfield, PhD
Associate Professor of Health Care Policy (Biostatistics),
Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Lori McLeod, PhD
Vice President, Patient-Centered Outcomes Assessment, RTI Health Solutions,
Research Triangle Park, NC, USA
James F. Murray, PhD
Research Fellow, Global Patient Outcomes and Real World
Evidence, Eli Lilly and Company, Indianapolis, IN, USA
Issue Panel/Workshop Review Committee
Blythe Adamson, PhD, MPH
Director of Quantitative Sciences, Flatiron Health,
New York, NY, USA
Gregory Daniel, PhD, MPH
Head,U. S. Healthcare Policy, Edwards Lifesciences,
Washington, DC, USA
Jessica Daw, PharmD
Vice President of Pharmacy, Optima Health,
Virginia Beach, VA, USA
Juan Marcos Gonzalez, PhD
Assistant Professor, Department of Population Health Sciences,
Duke University,
Durham, NC, USA
Bertalan Nemeth, MSc
Principal Researcher,
Syreon Research Institute,
Budapest, Hungary
Hemant Phatak, PhD
Head, Data Analytics and Value Assessment, North America Medical
Affairs at EMD Serono, Inc., Rockland, MA, USA
Claire Rothery, PhD
Senior Research Fellow in Health Economics,
Centre for Health Economics, University of York,
Heslington, York, UK
Maureen Smith, MEd
Board
Member, Canadian Organization for Rare Disorders (CORD) and Patient
Member, Ontario Committee to Evaluate Drugs and Ontario Health
Technology Assessment Committee,
Ontario, ON, Canada